These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 9669185

  • 1. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study.
    Terra JL, Montgomery SA.
    Int Clin Psychopharmacol; 1998 Mar; 13(2):55-62. PubMed ID: 9669185
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S, Volz HP, Möller HJ, Dienel A, Kieser M.
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
    Houck C.
    Psychopharmacol Bull; 1998 Nov; 34(2):225-7. PubMed ID: 9641005
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S.
    J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
    [Abstract] [Full Text] [Related]

  • 12. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 13. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D, Hooper CL, Filteau MJ, Charbonneau Y, Fraser G, West DL, Thibaudeau C, Raine D.
    Psychopharmacol Bull; 1996 Dec; 32(1):135-41. PubMed ID: 8927663
    [Abstract] [Full Text] [Related]

  • 14. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
    Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U.
    J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
    Anghelescu IG, Kohnen R, Szegedi A, Klement S, Kieser M.
    Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.